Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
- Pilotto, Sara
- Rossi, Antonio
- Vavalà, Tiziana
- Follador, Alessandro
- Tiseo, Marcello
- Galetta, Domenico
- Morabito, Alessandro
- Di Maio, Massimo
- Martelli, Olga
- Caffo, Orazio
- Piovano, Pier Luigi
- Cortinovis, Diego
- Zilembo, Nicoletta
- Casartelli, Clelia
- Banna, Giuseppe Luigi
- Ardizzoia, Antonio
- Barzelloni, Maria Luisa
- Bearz, Alessandra
- Genestreti, Giovenzio
- Mucciarini, Claudia
- Filipazzi, Virginio
- Menis, Jessica
- Rizzo, Elisa
- Barbieri, Fausto
- Rijavec, Erika
- Cecere, Fabiana
- Spitaleri, Gianluca
- Bria, Emilio
- Novello, Silvia
Publication date
January 2018
DOI Publisher
Elsevier BV ISSN
1525-7304 Citation count (estimate)
10Abstract
Beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study that reported the outcomes of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in a "real-life" Caucasian EGFR-mutated non-small-cell lung cancer (NSCLC) population. The sharing of multi-institutional experiences represents a crucial strategy to enrich knowledge about uncommon EGFR mutations. Therefore, we performed a post hoc analysis of the BE-POSITIVE study
Add to ORKG